Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Vertex Pharmaceuticals Inc (VRTX)

2K + Investors. Track Smart Money conviction in VRTX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +60
Streak
3Q ▲
Buyers last Q
54%

Smart Money Signals — VRTX

Based on 1756 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added VRTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
1,756 hedge funds hold VRTX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +14% more funds vs a year ago

fund count last 6Q
+211 new funds entered over the past year (+14% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 54% buying

916 buying768 selling
Last quarter: 916 funds bought or added vs 768 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+27 vs last Q)

new funds entering per quarter
Funds opening a new VRTX position: 152 → 278 → 170 → 197. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

65% of holders stayed for 2+ years

■ 65% conviction (2yr+) ■ 18% medium ■ 17% new
1,134 out of 1,756 hedge funds have held VRTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +88%, value +17%

Value
+17%
Shares
+87%
Last quarter: funds added +88% more shares while total portfolio value only changed +17%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~197 new funds/quarter

128 → 152 → 278 → 170 → 197 new funds/Q
New funds entering each quarter: 152 → 278 → 170 → 197. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 68% veterans vs 19% newcomers

■ 68% veterans ■ 13% 1-2yr ■ 19% new
Entry-cohort mix of 1,809 holders: 1,225 (68%) are 2+ year veterans, 235 entered 1–2 years ago, and 349 (19%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 74% AUM from top-100 funds

74% from top-100 AUM funds
71 of 1748 holders are among the 100 largest funds by AUM, controlling 74% of total institutional value in VRTX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — VRTX

In 2026 Q2, 916 hedge funds were net buyers of VRTX (197 opened a new position, 719 added to an existing one), while 768 reduced or exited (631 trimmed, 137 sold completely) — a 54% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 74% of total institutional value in VRTX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +60 funds (more new holders than closures). Total institutional holders: 1756.

Hedge Fund Ownership: VRTX

How many hedge funds hold VRTX — quarterly history vs. share price
Quarterly hedge fund ownership of VRTX vs. share price

Market Analysis: VRTX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: VRTX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Vertex Pharmaceuticals Inc (VRTX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much VRTX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 78d ago
VRTX
+4.6%
XLV
+5.7%

VRTX outperformed XLV by -1.1% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 33d ago
VRTX
+2.7%
XLV
+0.2%

Since the filing became public, VRTX outperformed XLV by +2.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

58 top-rated funds 9 high-conviction
Consensus
7.7
/ 10
breadth
×
Elite
3.6
/ 10
conviction
Hedge Fund Positioning: VRTX
2K + Investors

Track Smart Money conviction in VRTX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 1734 1696 2.24%
13F Shares 243M 231M 5.24%
Total Value $117.69B $100.91B 16.64%
New Positions 194 170 +24
Increased Positions 700 676 +24
Closed Positions 148 129 +19
Reduced Positions 612 589 +23
Total Calls 31 34 -8.82%
Total Puts 29 30 -3.33%
PUT/CALL Ratio 0.94 0.88 Neutral

Statistics: VRTX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

2K + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VRTX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 VRTX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Tri Locum Partners LP 12.33% 201,791 $100.2M
2 Provident Investment Management, Inc. 6.79% 140,728 $69.9M
3 Bellevue Group AG 6.05% 578,634 $287.4M
4 Andrew Hill Investment Advisors, Inc. 4.88% 13,232 $6.6M
5 Motley Fool Wealth Management, LLC 4.80% 636 $316K
6 Eurizon SLJ Capital Ltd 4.21% 22,969 $11.4M
7 Mcrae Capital Management Inc 3.24% 33,191 $16.5M
8 Nia Impact Advisors, LLC 3.02% 14,663 $7.3M
9 Birch Hill Investment Advisors LLC 2.97% 147,702 $73.4M
10 Shelter Mutual Insurance Co 2.90% 27,600 $13.7M
11 AIMZ Investment Advisors, LLC 2.72% 19,931 $9.9M
12 Edgewood Management LLC 2.72% 531,003 $263.8M
13 Bender Robert & Associates 2.72% 26,303 $13.1M
14 Private Harbour Investment Management & Counsel, LLC 2.59% 4,395 $2.2M
15 Atle Fund Management AB 2.56% 19,131 $9.5M
16 Mark Sheptoff Financial Planning, LLC 2.45% 9,295 $4.6M
17 Loomis Sayles & Co L P 2.44% 3,920,953 $1.95B
18 Graphene Investments SAS 2.17% 7,500 $3.7M
19 AlphaCentric Advisors LLC 2.11% 5,002 $2.5M
20 Puzo Michael J 2.04% 15,907 $7.9M
21 Elefante Mark B 1.99% 9,285 $4.6M
22 Dempze Nancy E 1.97% 8,282 $4.1M
23 Somerville Kurt F 1.95% 16,441 $8.2M
24 Hemenway Trust Co LLC 1.94% 55,995 $27.8M
25 Cullinan Associates Inc 1.94% 51,762 $25.7M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Vertex Pharmaceuticals Inc (VRTX)

What does the Smart Money Trend signal show for VRTX?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added VRTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for VRTX?

Slight buying edge — 54% buying: Last quarter: 916 funds bought or added vs 768 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for VRTX holders?

Elite ownership — 74% AUM from top-100 funds: 71 of 1748 holders are among the 100 largest funds by AUM, controlling 74% of total institutional value in VRTX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held VRTX?

65% of holders stayed for 2+ years: 1,134 out of 1,756 hedge funds have held VRTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Vertex Pharmaceuticals Inc (VRTX) following the 2026 Q2 hedge fund 13F filings?

As of today, VRTX has moved +2.7% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.2% for the XLV sector ETF — an outperformance of +2.5%. Since the quarter end (June 30, 2026), VRTX has gained +4.6% vs +5.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →